Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia

Annals of Hematology

Volumn 91, Issue 12, 2012, Pages 1937-1943

  Damiani, Daniela ^a   Tiribelli, Mario ^a   Geromin, Antonella ^a   Cerno, Michela ^a   Sperotto, Alessandra ^a   Toffoletti, Eleonora ^a   Simeone, Erica ^a   Michelutti, Angela ^a   Cavallin, Margherita ^a   Fanin, Renato ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Allogeneic transplant; AML; Refractory; Relapsed

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; THIOTEPA;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTEREMIA; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; CONTINUOUS INFUSION; CYTOMEGALOVIRUS INFECTION; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HERPES SIMPLEX; HISTOCOMPATIBILITY; HUMAN; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; PNEUMONIA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SIBLING; STOMACH HEMORRHAGE; TREATMENT OUTCOME; UNRELATED DONORS; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HLA ANTIGENS; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; ITALY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84871029025     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1551-x     Document Type: Article

References (24)

1. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH (2006) Age and acute myeloid leukemia. Blood 107(9):3481-3485
2. Walter RB, Appelbaum FR, Tallman MS, Weiss NS, Larson RA, Estey EH (2010) Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood 116(14):2420-2428
3. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116(3):354-365
4. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3):453-474
5. Breems DA, BoogaertsMA,Dekker AW,Van PuttenWL, Sonneveld P, Huijgens PC, Van der Lelie J, Vellenga E, Gratwohl A, Verhoef GE, Verdonck LF, Lowenberg B (2005) Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. Br J Haematol 128(1):59-65
6. Armistead PM, de Lima M, Pierce S, Qiao W, Wang X, Thall PF, Giralt S, Ravandi F, Kantarjian H, Champlin R, Estey E (2009) Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant 15(11):1431-1438
7. Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T, Dini G, Rocha V, Passweg J, Sureda A, Tichelli A, Niederwieser D (2009) Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 115(20):4715-4726
8. Hemmati PG, Terwey TH, le Coutre P, Vuong LG, Massenkeil G, Dorken B, Arnold R (2011) A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants. Eur J Haematol 86(4):305-316
9. Sorror ML, Sandmaier BM, Storer BE,MarisMB, Baron F, Maloney DG, Scott BL, Deeg HJ, Appelbaum FR, Storb R (2007) Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 25 (27):4246-4254
10. Vigorito AC, Campregher PV, Storer BE, Carpenter PA, Moravec CK, Kiem HP, Fero ML, Warren EH, Lee SJ, Appelbaum FR, Martin PJ, Flowers ME (2009) Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 114(3):702-708
11. Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40 (4):381-387
12. Kim DH, Sohn SK, Kim JG, Lee NY, Sung WJ, Baek JH, Suh JS, Lee KS, Lee KB (2005) Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation. Ann Hematol 84 (1):25-32
13. Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Sakura T, Kanamori H, Usuki K, Yamashita T, Okoshi Y, Shibayama H, Nakamae H, Mawatari M, Hatanaka K, Sunami K, Shimoyama M, Fujishima N, Maeda Y, Miura I, Takaue Y, Fukuda T (2010) Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse. Haematologica 95(11):1857-1864
14. Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, Kamble R, Copelan E, de Lima M, Gupta V, Keating A, Lazarus HM, Litzow MR, Marks DI, Maziarz RT, Rizzieri DA, Schiller G, Schultz KR, Tallman MS, Weisdorf D (2010) Hematopoietic stemcell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 28(23):3730-3738
15. Naik S, Wong R, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Blume K, Negrin R, Johnston L (2011) Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Bone Marrow Transplant 46(2):192-199
16. Valcarcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Pinana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simon JA, Sierra J (2008) Sustained remissions of high-risk acutemyeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 26 (4):577-584
17. Koh H, Nakamae H, Hagihara K, Nakane T, Manabe M, Hayashi Y, Nishimoto M, Umemoto Y, Nakamae M, Hirose A, Inoue E, Inoue A, Yoshida M, Bingo M, Okamura H, Aimoto R, Aimoto M, Terada Y, Koh KR, Yamane T, Ohsawa M, Hino M (2011) Factors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation. J Exp Clin Cancer Res 30:36
18. Oyekunle AA, Kroger N, Zabelina T, Ayuk F, Schieder H, Renges H, Fehse N, Waschke O, Fehse B, Kabisch H, Zander AR (2006) Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up. Bone Marrow Transplant 37(1):45-50
19. Shimoni A, Nagler A (2011) Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need. Best Pract Res Clin Haematol 24 (3):369-379
20. Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE (2011) Clofarabine +/+ fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 17(6):893-900
21. Birninger N, Bornhauser M, Schaich M, Ehninger G, Schetelig J (2011) The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation- investigation of potential limitations of the index. Biol Blood Marrow Transplant 17(12):1822-1832
22. Michallet M, Thomas X, Vernant JP, Kuentz M, Socie G, Esperou-Bourdeau H, Milpied N, Blaise D, Rio B, Reiffers J, Jouet JP, Cahn JY, Bourhis JH, Lioure B, Leporrier M, Sotto JJ, Souillet G, Sutton L, Bordigoni P, Dreyfus F, Tilly H, Gratecos N, Attal M, Leprise PY, Demeocq F, Michel G, Buzyn A, Delmas-Marsalet B, Bernaudin F, Ifrah N, Sadoun A, Guyotat D, Cavazzana-Cavo M, Caillot D, De Revel T, Vannier JP, Baruchel A, Fegueux N, Tanguy ML, Thiebaut A, Belhabri A, Archimbaud E (2000) Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant 26 (11):1157-1163
23. Sierra J, Radich J, Hansen JA, Martin PJ, Petersdorf EW, Bjerke J, Bryant E, Nash RA, Sanders JE, Storb R, Sullivan KM, Appelbaum FR, Anasetti C (1997) Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 90(4):1410-1414
24. Schlenk RF, Dohner K, Mack S, Stoppel M, Kiraly F, Gotze K, Hartmann F, Horst HA, Koller E, Petzer A, Grimminger W, Kobbe G, Glasmacher A, Salwender H, Kirchen H, Haase D, Kremers S, Matzdorff A, Benner A, Dohner H (2010) Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 28(30):4642-4648